This information is updated frequently and will continue to evolve. We will keep you posted of significant developments as they occur. If you have any questions on these materials, please contact Joel Kopperud at joel.kopperud@ciab.com.

The Council’s Positions

The Council’s largest priority in this fight is the preservation of Employer-Sponsored Insurance. Employer-Sponsored Insurance (ESI) is the most common type of health coverage in the United States, with more than 177 million Americans depending on it. But some in Congress want to tax employees on the cost of their health care benefits.

Imposing a tax on employer-sponsored health plans is a dangerous policy experiment that could significantly erode employer-sponsored health coverage. Any cap on the tax exclusion is a direct tax on employees and the middle class.

Click here to see our full page on ESHI.

The Council is also continuing to fight against the Cadillac Tax. The Affordable Care Act includes a 40% excise tax on employer-sponsored health plans with annual premiums exceeding $10,200 for individuals or $27,500 for families (the amount exceeding the threshold is taxed at 40%). Most predictions indicate that a significant number of group health plans would trigger the 40 percent excise tax if there aren’t any adjustments made to the threshold. This has been dubbed the “Cadillac Tax” referring to high-cost health plans.

You can learn more about the Cadillac Tax here.

Get the Latest

See more by reading the latest Healthcare in Transition newsletter, below.

Questions?

Please contact Joel Wood at joel.wood@ciab.com or Joel Kopperud at joel.kopperud@ciab.com with any questions.

Healthcare in Transition Spotlight

1332 Section Waiver Changes
Healthcare In Transition | Nov. 8, 2018 | Healthcare

The Department of Health and Human Services (HHS) released new guidance on Section 1332 State Innovation Waivers under the ACA with the goal of reducing burdens on states applying for

ACA Reform Legislation Tracker as of October 2018
Healthcare In Transition | Nov. 8, 2018 | Healthcare

Our legal team at Steptoe & Johnson tracks healthcare reform bills as they are introduced in Congress. Check out the most recent updates as of October on the first page

Drug Pricing on TV
Healthcare In Transition | Nov. 8, 2018 | Healthcare

The CMS proposed that drug manufacturers be required to disclose the list prices of drugs covered by Medicare or Medicaid in TV ads. In particular, manufacturers would have to include

Pharmacy Supply Chain: What You Need to Know
Healthcare In Transition | Nov. 8, 2018 | Drug Pricing

Pharmacy Supply Chain: What You Need to Know Despite the Trump administration’s push to lower drug prices, costs have not yet decreased. Lack of consensus regarding how to approach the

Midterm Implications for Healthcare
Healthcare In Transition | Nov. 8, 2018 | ACA, Government Affairs, Healthcare

Healthcare proved significant to voters on Tuesday, but it was not quite pivotal. Democrats scored a majority in the House, while Republicans expanded their majority in the Senate. Hence, legislative

The HRA Rule
Healthcare In Transition | Nov. 8, 2018 | Healthcare

The Trump administration proposed a rule to allow employers to offer Health Reimbursement Arrangements (HRAs) integrated with individual insurance coverage – an option previously only allowed for group coverage. The

Medicare Part B Drug Pricing to Mirror Foreign Prices?
Healthcare In Transition | Nov. 8, 2018 | Healthcare

CMS released an advanced notice of proposed rulemaking—with the spring of 2019 targeted for a proposed rule—describing changes to the way Medicare pays for some drugs administered by doctors. The

Resources

1332 Section Waiver Changes

The Department of Health and Human Services (HHS) released new guidance on Section 1332 State Innovation Waivers under the ACA with the goal of reducing burdens on states applying for

ACA Reform Legislation Tracker as of October 2018

Our legal team at Steptoe & Johnson tracks healthcare reform bills as they are introduced in Congress. Check out the most recent updates as of October on the first page

Drug Pricing on TV

The CMS proposed that drug manufacturers be required to disclose the list prices of drugs covered by Medicare or Medicaid in TV ads. In particular, manufacturers would have to include

Pharmacy Supply Chain: What You Need to Know

Pharmacy Supply Chain: What You Need to Know Despite the Trump administration’s push to lower drug prices, costs have not yet decreased. Lack of consensus regarding how to approach the

Midterm Implications for Healthcare

Healthcare proved significant to voters on Tuesday, but it was not quite pivotal. Democrats scored a majority in the House, while Republicans expanded their majority in the Senate. Hence, legislative

The HRA Rule

The Trump administration proposed a rule to allow employers to offer Health Reimbursement Arrangements (HRAs) integrated with individual insurance coverage – an option previously only allowed for group coverage. The

Medicare Part B Drug Pricing to Mirror Foreign Prices?

CMS released an advanced notice of proposed rulemaking—with the spring of 2019 targeted for a proposed rule—describing changes to the way Medicare pays for some drugs administered by doctors. The

AHPs – InsureTech Connect Breakdown – Short-Term Health Plans

Association Health Plans: The Lowdown from Our Legal Counsel Scott Sinder, partner at Steptoe & Johnson and chief legal officer for The Council, breaks down what the new AHP regulation

Cigna-Express Scripts Deal Gets the Green Light

Click to read The Council perspective.